Baseline surveillance in li-fraumeni syndrome using whole-body magnetic resonance imaging ameta-analysis

JAMA Oncology

Volumn 3, Issue 12, 2017, Pages 1634-1639

  Ballinger, Mandy L ^a   Best, Ana ^b   Mai, Phuong L ^b   Khincha, Payal P ^b   Loud, Jennifer T ^b   Peters, June A ^b   Achatz, Maria Isabel ^b,c   Chojniak, Rubens ^c   Balieiro Da Costa, Alexandre ^c   Santiago, Karina Miranda ^c   Garber, Judy ^d   O'Neill, Allison F ^d   Eeles, Rosalind A ^e   Evans, D Gareth ^f   Bleiker, Eveline ^g   Sonke, Gabe S ^g   Ruijs, Marielle ^g   Loo, Claudette ^g   Schiffman, Joshua ^h   Naumer, Anne ^h   Kohlmann, Wendy ^h   Strong, Louise C ⁱ   Bojadzieva, Jasmina ⁱ   Malkin, David ^j,k   Rednam, Surya P ^l   Stoffel, Elena M ^m   Koeppe, Erika ^m   Weitzel, Jeffrey N ⁿ   Slavin, Thomas P ⁿ   Nehoray, Bita ⁿ   Robson, Mark ^o   Walsh, Michael ^o   Manelli, Lorenzo ^o   Villani, Anita ^j   Thomas, David M ^a   Savage, Sharon A ^b   more..

^a GarvanInstitute of Medical Research   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f ST MARY S HOSPITAL   (United Kingdom)

^g ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; HEALTH SURVEY; HUMAN; LI-FRAUMENI SYNDROME; MALE; META ANALYSIS; MIDDLE AGED; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROCEDURES; WHOLE BODY IMAGING; YOUNG ADULT;

ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LI-FRAUMENI SYNDROME; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; TUMOR SUPPRESSOR PROTEIN P53; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 85033598751     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.1968     Document Type: Article

References (31)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-752.
2. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38(1):43-47.
3. Bougeard G, Sesboüé R, Baert-Desurmont S, et al; French LFSWorking Group. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008;45(8):535-538.
4. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345-2352.
5. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27(26): e108-e109; author reply e110.
6. Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82(12):1932-1937.
7. Wu CC, Shete S, Amos CI, Strong LC. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66(16): 8287-8292.
8. Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673-3681.
9. Peters JA, Kenen R, Bremer R, Givens S, Savage SA, Mai PL. Easing the burden: describing the role of social, emotional and spiritual support in research families with Li-Fraumeni syndrome. J Genet Couns. 2016;25(3):529-542.
10. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250 (4985):1233-1238.
11. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747-749.
12. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19(6):607-614.
13. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3): 313-320.
14. Daly MB, Pilarski R, Berry M, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian, Version 2.2017. https://www.nccn.org/professionals/physician_gls /pdf/genetics_screening.pdf. December 7, 2016. Accessed March 2, 2017.
15. The National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE clinical guideline 164. https://www.nice.org.uk/guidance/CG164. June 2013. Updated March 2017. Accessed March 2, 2017.
16. Cancer Institute NSW. eviQ Cancer treatments online: risk management for adults with a TP53 mutation. https://www.eviq.org.au/Protocol/tabid /66/categoryid/66/id/749/Risk+Management+for +adults+with+a+TP53+Mutation+.aspx. Updated June 7, 2017. Accessed March 2, 2017.
17. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295-1305.
18. Custódio G, Parise GA, Kiesel Filho N, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2013; 31(20):2619-2626.
19. Saya S, Killick E, Thomas S, et al; SIGNIFY Study Steering Committee. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. FamCancer. 2017;16(3):433-440. doi:10.1007 /s10689-017-9965-1 20.
20. McBride KA, Ballinger ML, Schlub TE, et al. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? FamCancer. 2017;16(3):423-432.
21. Mai PL, Malkin D, Garber JE, et al. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012;205(10):479-487.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
23. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat. 1998;52(2):119-126.
24. R Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statisical Computing; 2016.
25. Schwarzer G. meta: An R package for meta-analysis.RNews. 2007:40-45.
26. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario High Risk Breast Screening Program. J Clin Oncol. 2014;32(21): 2224-2230.
27. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-8476.
28. Leach MO, Boggis CR, Dixon AK, et al; MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365(9473):1769-1778.
29. Kriege M, Brekelmans CT, Obdeijn IM, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat. 2006;100(1):109-119.
30. Evans DG, Lennard F, Pointon LJ, et al; UK Study of MRI Screening for Breast Cancer inWomen at High Risk (MARIBS). Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2123-2131.
31. Dryden R, Williams B, McCowan C, Themessl-Huber M. What do we know about who does and does not attend general health checks? findings from a narrative scoping review. BMC Public Health. 2012;12:723.